Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.
about
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents.Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulationsGastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatmentSingle oral dose study of two isosorbide-based aspirin prodrugs in the dogThe risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of gastroprotective drugsEffects of buffered and plain acetylsalicylic acid formulations with and without ascorbic acid on gastric mucosa in healthy subjectsConcomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugsAspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trialsA clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugsRole of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug usersRole of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin CAssociation between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studiesRisk of gastric injury with enteric- versus nonenteric-coated aspirinUpper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in DenmarkGastrointestinal tolerability of ibuprofen compared with paracetamol and aspirin at over-the-counter dosesRisk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseasesAspirin resistance and its implications in clinical practiceUpper gastrointestinal bleeding associated with antiplatelet drugsPrimary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national surveyDifferences in the effects of extended-release aspirin and plain-formulated aspirin on prostanoids and nitric oxide in healthy volunteersTreatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleedingAdverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tractReview article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyondChemoprevention of colorectal cancerRisk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC studyAspirin and other NSAIDs as chemoprevention agents in melanomaBleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis.Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.Effect of Low-dose, Enteric Coated Aspirin on Gastrointestinal Bleeding in Patients with Coronary Artery DiseaseRisk of upper gastrointestinal bleeding associated with use of low-dose aspirin.Drugs used in secondary prevention after myocardial infarction: case presentation.Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract.NSAID-related gastrointestinal injury. Evidence-based approach to a preventable complication.Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.Long-term use of aspirin and the risk of gastrointestinal bleeding.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Risk management of risk management: Combining proton pump inhibitors with low-dose aspirinReview article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
P2860
Q21195670-9ED8845A-F4AA-4E01-A0FC-55439968D011Q22241777-C75B64E6-3319-4207-AE36-AEE2B9238834Q24798492-0368D75C-E5F0-4CD1-B7D5-B8A007B192F7Q27027977-D2F5FBD8-C703-40EA-9746-51F7067F9337Q28166016-035E889A-CB31-491D-A82E-A3308F04CA92Q28167214-DD8EB876-DE5B-4F09-AC78-B94C896F212AQ28167440-1EBE2974-A20D-447B-981D-6AA2C7800E16Q28168123-BDFAC636-E337-4BC3-8F62-23B64C386209Q28175861-90D3FAB6-6B92-498E-9B9B-DB19981B7740Q28176840-E672612D-88BB-4EFD-ABCF-578F792981DEQ28182449-B6FB456F-9E2A-48C0-A4E6-84BB83F903D7Q28182648-4D9931E8-CB4C-40FE-A0AE-A2BF64D0708EQ28191843-A1108DE4-8BF0-42CE-9020-3752B7FF149BQ28192241-C7B0D8B5-2A75-49F7-AF3D-E8402022E503Q28192383-96DF7C20-B981-4A49-AB9D-4060540BBE5AQ28193558-F921E1B4-0586-4BF8-8EF9-E70A3A76433AQ28193996-57F377E8-CF69-4C09-91CF-E947A08D7087Q28194069-DE0E3215-D2FD-44E7-9E3B-3CC2FF89340BQ28194354-B7634BDE-2A56-425B-A706-BEEACB9C6466Q28195079-789BA982-E95E-4FDA-A541-4D2CC1C2D676Q28196435-4BDC38DD-0570-4CCB-9E8A-9E974830FD3DQ28198718-8BC8E730-434C-4D8F-9313-347A8634B5C2Q28199102-52A6BC79-9635-4CED-A13F-D519363FFFBFQ28200403-27927393-A8EA-4A1B-96AC-67BC5A36BE92Q28210656-E40DD599-EA29-4356-AF67-ED38DF1EDDBCQ28369263-D3DBA758-CB3D-4B0E-A6E8-DB11FEB555C7Q33605890-0BF0525F-6E4E-40CC-9719-386A42890902Q33725012-34C5DF06-9938-4205-8CE0-3373CB3A299EQ33727851-BADD6509-41BE-4B8B-8525-DA192A60F494Q33822140-7E038D02-F7EA-4759-BAC6-9AFFA5ECECA9Q33855588-BC694D9F-1D4F-4E45-80FB-6C78A5BA7B81Q33919442-3CF23241-C86C-4261-A242-DCFC6A1B4E45Q34078583-DEA648E9-F119-4C87-B884-792EF133A5EAQ34095700-F8A70D9F-1CC4-40FA-B452-73D56EAB7993Q34379920-D87CD617-654C-4696-8DA8-CFBC62BFFEA8Q34433987-BDE46A3F-384F-44A0-98C0-1394AB23D780Q34628874-0B8544FB-DB44-4013-9530-1D8CEB9F8B18Q34771381-35E21D7D-5FD5-45C4-A53E-D6F70BB81CECQ35026472-963EA42F-4E93-4D62-8F10-46D2A8CE5230Q35058190-89679AB2-6B00-420B-8E96-E31A494BA2AA
P2860
Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Risk of aspirin-associated maj ...... ic-coated or buffered product.
@en
Risk of aspirin-associated maj ...... ic-coated or buffered product.
@nl
type
label
Risk of aspirin-associated maj ...... ic-coated or buffered product.
@en
Risk of aspirin-associated maj ...... ic-coated or buffered product.
@nl
prefLabel
Risk of aspirin-associated maj ...... ic-coated or buffered product.
@en
Risk of aspirin-associated maj ...... ic-coated or buffered product.
@nl
P2093
P1433
P1476
Risk of aspirin-associated maj ...... ic-coated or buffered product.
@en
P2093
P304
P356
10.1016/S0140-6736(96)01254-8
P407
P577
1996-11-01T00:00:00Z